Transitioning from a capital markets CEO to a pharma CEO is a smart move for a licensed cannabis producer about to rapidly expand its output, and that’s exactly what Abcann Global (ABCN.V) did this morning, in announcing a new Chief Executive in former Merus Labs (MSL.T, MSLI:NASDAQ), Teva Canada, and Taro Canada CEO, Barry Fishman.

Former Abcann CEO Aaron Keay will stay on as a director, and will focus on the public markets and potential M&A activity.

ABCN stock has had an up and down run since it went public earlier this year, but never dipped below 18% from its opening price, despite a general slump in the marijuana market.

With streaming deals struck with Cannabis Wheaton (CBW.V) helping to finance a substantial expansion to the company growing operations, from 30k sq ft to 150k sq ft in Napanee, Ontario, under Keay’s leadership, the firm also shifted into opportunities in Australia, Israel, and Germany. I’m told it’s likely around $12m has been received by the company recently in warrants, which would put the cash position of the organization at around $48 million – around half its current market cap.

In Fishman, the company has a seasoned chief executive who formerly served as VP of Marketing at Pfizer, and took Merus Labs to a $342 million takeover by Norgine B.V as recently as July of this year. To sign him so soon after a nine-figure exit is quite the coup.

In terms of marijuana experience, he currently sits on the board of Aurora Cannabis (ACB.V), and was on the board of Bedrocan when it was taken out by Canopy Growth (WEED.T).

He takes over an outfit that is renowned in the business for consistent, high quality product that has previously been purchased by competitors for resale. The company tells me it’s getting around 300 grams per sq. ft in yield, which according to our research places it way above every other producer bar MedReleaf (LEAF.T).

The company sits on an undervalued $84 million market cap as the weed space looks to be picking up steam.

— Chris Parry

FULL DISCLOSURE: Abcann Global is an Equity.Guru marketing client

Written By:

Chris Parry

A multi-Webster Award winner for excellence in BC journalism, Parry is the founder and publisher of Equity.Guru, which he built with the specific plan to blend old school reporting with stock promotion, in a way that puts the emphasis on truth, high standards, and ethics. Parry is a veteran of TV, radio, and print, and consults with public companies to help them figure out their storylines, lay down achievable milestones, and improve their communication with shareholders, while also posting regular deep dive analysis of companies in the public spotlight.

More By This Author
Tags:
Biotech
Cannabis
Growing
Health Science
Parry
Pharmaceuticals
Abcann Medicinals
ABCN.V
cannabis
Medical marijuana
pharmaceuticals
Vivo Cannabis
VIVO.V
0 0 votes
Article Rating
Subscribe
Notify of
guest
3 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
3
0
Would love your thoughts, please comment.x
()
x